Concepedia

Gary Borzillo

GB

Statistics

Publications

13

Citations

841

H-Index

12

Active since

1989

Affiliations

Pfizer (United States)(Current)

St. Jude Children's Research Hospital

Howard Hughes Medical Institute

Kettering University

Massachusetts General Hospital

Gary Borzillo is an author at Pfizer (United States) specializing in pharmacology, oncology, and molecular oncology.

ORCID

Publications per year

1989–2015

13

Publications

13

Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened

Michael J. Munchhof, Qifang Li, Andrei Shavnya et al. · ACS Medicinal Chemistry Letters · 2011 · 160 citations · Full text

, , +16

Macrophage lineage switching of murine early pre-B lymphoid cells expressing transduced fms genes.

Gary Borzillo, RA Ashmun, Charles J. Sherr · Molecular and Cellular Biology · 1990 · 126 citations

, , +17

First-in-Human Study of PF-05212384 (PKI-587), a Small-Molecule, Intravenous, Dual Inhibitor of PI3K and mTOR in Patients with Advanced Cancer

Geoffrey I. Shapiro, Katherine M. Bell‐McGuinn, Julian R. Molina et al. · Clinical Cancer Research · 2015 · 117 citations · Full text

, , +15

Design of Selective, ATP-Competitive Inhibitors of Akt

Kevin D. Freeman‐Cook, Christopher Autry, Gary Borzillo et al. · Journal of Medicinal Chemistry · 2010 · 77 citations · Full text

, , +17

Synthesis and structure based optimization of novel Akt inhibitors

Blaise Lippa, Gonghua Pan, Matthew S. Corbett et al. · Bioorganic & Medicinal Chemistry Letters · 2008 · 76 citations · Full text

, , +12

1–5 of 13